Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust ...

Photoshop CC 2020 tutorial showing how to create a portrait poster of yourself or someone you know in the style of classic, letterpress printing. ➤ Get 15% off BORIS FX OPTICS! - The Academy & Emmy ...

Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for a poster presentation at the 2025 American Society of Clinical Oncology Annual Meeting, scheduled for May 30 to June ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple ...

will be highlighted in an oral presentation. In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic ...

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of PathAI's pathology universal ...

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of PathAI's pathology universal ...

The abstract submission deadline is April 21, 2025. In addition to oral presentation awards, competitively selected research posters will be judged during the conference in Poster Presentation ...